Tacoma
Excision Reveals the Next Chapter of “The Thunderdome”
Grab your neckbrace—it’s almost time to enter the Thunderdome. Outside of Excision‘s world-class festivals, Lost Lands and Bass Canyon, are a number of ancillary events that amass a congregation of headbangers and bass music enthusiasts from all over the world. One of the most notable of these branded events is “The Thunderdome,” which brings some of the biggest artists in bass out to the West Coast for an intense two-day audiovisual experience. This afternoon Excision revealed who will be joining him at the electrifying show in Tacoma next year. Accompanying him and his jaw-dropping Evolution stage production are Liquid Stranger, 12th Planet, ATLiens, Dion Timmer, Riot Ten, Vampa, Blunts & Blondes, JEANIE, Kompany, Ray Volpe, and more. The event is spread out o...
US election: Republicans hold back Democrats, narrowing path to Senate control
The battle for power in the Senate tightened into Wednesday as Democrats picked up a seat in Colorado, but suffered a setback in Alabama, and Republicans held their own in high-profile races in South Carolina, Iowa, Texas and Kansas, dramatically narrowing the political map. Republicans fought to retain their Senate majority by turning back a surge of Democrats challenging allies of President Donald Trump, and the Democrats’ various paths to seizing control were growing more limited. With several contests still too early to call, and one Georgia race heading to a January runoff, the final verdict is expected to drag on. Democrats gained a seat when ex-Gov. John Hickenlooper ousted GOP Sen. Cory Gardner in Colorado, a must-win to flip the Senate, but couldn’t hold on in Alabama, where forme...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
